Zdrowie i gospodarka · 11/08/2023

FDA Publishes Draft Guidance on Postmarketing Approaches for Under-Represented Populations in Clinical Trials

The US Food and Drug Administration (FDA) has released a draft guidance for industry outlining requirements and recommendations for collecting safety and effectiveness data on under-represented patient groups in postmarketing clinical trials, following historically under-represented populations in clinical trials.